A cost-effectiveness analysis of patiromer for the treatment of hyperkalemia in chronic kidney disease patients with and without heart failure in Spain

References

• Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the global burden of disease study 2015. The Lancet. 2016;388(10053):640–1544.
   PubMed Web of Science ®Google Scholar
• Ballarín J, García F, Ibeas J, et al. Guía de Práctica Clínica sobre la Detección y el Manejo de la Enfermedad Renal Crónica del Servicio Nacional de Salud [Clinical practice guideline on detection and management of the chronic kidney disease. Ministerio de Sanidad, Servicios Sociales e Igualdad. Instituto Aragonés de Ciencias de la Salud [Internet]. 2016 [cited 2021 August 17]. Available from: https://portal.guiasalud.es/wp-content/uploads/2018/12/GPC_559_ERC_IACS_compl.pdf.
   Google Scholar
• Evans M, Palaka E, Furuland H, et al. The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease. BMC Nephrol. 2019;20(1):31.
   PubMed Web of Science ®Google Scholar
• Belmar L, Galabia ER, Bada da Silva J, et al. Epidemiología de la hiperpotasemia en la enfermedad renal crónica [epidemiology of hyperkalemia in chronic kidney disease]. Nefrología. 2019;39(3):277–286. Spanish.
   PubMed Web of Science ®Google Scholar
• Sterns RH, Rojas M, Bernstein P, et al. Ion-Exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. 2010;21(5):733–735.
   PubMed Web of Science ®Google Scholar
• AEMPS (Spanish Agency for Medicines and Medical Devices). AEMPS online medicinal product information centre (CIMA). AEMPS [Internet]. 2021 [cited 2021 November 18]. Available from: https://cima.aemps.es/cima/publico/home.html.
   Google Scholar
• Olry de Labry A, Díaz Ó, Romero-Requena JM, et al. Hyperkalaemia management and related costs in chronic kidney disease patients with comorbidities in Spain. Clin Kidney J. 2021;14(11):2391–2400.
   PubMed Web of Science ®Google Scholar
• Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211–221.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Patiromer for treating hyperkalaemia: guidance (TA623). National Institute for Health and Care Excellence [Internet]. 2020 [cited 2020 December 9]. Available from: https://www.nice.org.uk/guidance/ta623
   Google Scholar
• VIFOR PHARMA. OPAL-HK CSR. Data on file. 2014.
   Google Scholar
• Ortega A, Marín R, Fraga MD. Guía de evaluación económica e impacto presupuestario en los informes de evaluación de medicamentos. Guía práctica asociada al programa MADRE v 4.0. [Guideline for economic evaluation and budget impact in drug evaluation reports. Practice guideline associated with the MADRE v 4.0. program]. Sociedad Española de Farmacia Hospitalaria. 2021 [cited 2021 July 1]. Available from: https://gruposdetrabajo.sefh.es/genesis/genesis/Documents/GUIA_EE_IP_GENESIS-SEFH_19_01_2017.pdf.
   Google Scholar
• Horne L, Ashfaq A, MacLachlan S, et al. Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England. BMC Nephrol. 2019;20(1):85.
   PubMed Web of Science ®Google Scholar
• Linde C, Bakhai A, Furuland H, et al. Real‐world associations of renin–angiotensin–aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new‐onset chronic kidney disease or heart failure in the United Kingdom. JAHA. 2019;8(22):e012655.
   Web of Science ®Google Scholar
• Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. The Lancet. 2000;355(9215):1575–1581.
   PubMed Web of Science ®Google Scholar
• Cooper BA, Branley P, Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010;363(7):609–619.
   PubMed Web of Science ®Google Scholar
• Robb M, Hendry R. Annual report on kidney transplantation. NHS Blood and Transplant [Internet]. 2020 [cited 2021 December 9]. Available from: https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/20032/kidney-annual-report-2019-20-final.pdf.
   Google Scholar
• UK Renal Association. UK Renal Registry 22nd Annual Report. UK Renal Association [Internet]. 2018 [cited 2021 December 9]. Available from: https://ukkidney.org/about-us/who-we-are/uk-renal-registry.
   Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305.
   PubMed Web of Science ®Google Scholar
• Yao G, Freemantle N, Calvert MJ, et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Euro Heart J. 2006;28(1):42–51.
   PubMed Web of Science ®Google Scholar
• Ford E, Adams J, Graves N. Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia. BMJ Open. 2012;2(5):e001094.
   PubMed Web of Science ®Google Scholar
• Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67(5):728–741.
   PubMed Web of Science ®Google Scholar
• Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113(11):1424–1433.
   PubMed Web of Science ®Google Scholar
• Nuijten M, Andress DL, Marx SE, et al. Cost effectiveness of paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK. Clin Drug Investig. 2010;30(8):545–557.
   PubMed Web of Science ®Google Scholar
• Gisbert R, Brosa M. Base de Datos de Costes Sanitarios y Ratios Coste-Efectividad Españoles: eSalud [Database of Spanish health costs and cost-effectiveness ratios]. Oblikue Consulting S.L. [Internet]. 2021 [cited 2021 June 2]. Available from: http://esalud.oblikue.com.
   Google Scholar
• Lorenzo-Sellares V, Pedrosa MI, Santana-Expósito B, et al. Análisis de costes y perfil sociocultural del enfermo renal. Impacto de la modalidad de tratamiento [cost analysis and sociocultural profile of kidney patients. Impact of the treatment method]. Nefrología. 2014;34:458–468. Spanish.
   PubMed Web of Science ®Google Scholar
• Caballero Alcalde C, Calleja Hernández MA, Escoda Ruiz L, et al. Libro blanco de la poliquistosis renal autosomica dominante (PQRAD) en España. Alianza frente a la PQRAD. 2nd Ed. 2016. Available from: https://www.easp.es.
   Google Scholar
• Darbà J, Marsà A. Chronic kidney disease in Spain: analysis of patient characteristics, incidence and direct medical costs (2011–2017). J Med Econ. 2020;23(12):1623–1629.
   PubMed Web of Science ®Google Scholar
• Vargas M. Documento Marco sobre Enfermedad Renal Crónica dentro de la Estrategia de Abordaje a la Cronicidad en el SNS. Ministerio De Sanidad Servicios Sociales E Igualdad [Document on chronic kidney disease within the chronicity approach strategy in the NHS]. Ministerio de Sanidad, Servicios Sociales e Igualdad [Internet]. 2015 [cited 2021 may 28]. Available from: https://www.sanidad.gob.es/organizacion/sns/planCalidadSNS/pdf/Enfermedad_Renal_Cronica_2015.pdf.
   Google Scholar
• Ministerio de Sanidad. Conjunto Mınimo Basico de Datos (CMBD) [Minimum basic data set (MBDS)]. Ministerio de Sanidad [Internet]. 2019 [cited 2021 July 1]. Available from: https://www.sanidad.gob.es/estadEstudios/estadisticas/cmbdhome.htm.
   Google Scholar
• Consejo General de Colegios Oficiales de Farmacéuticos. Portal Farma. BotPLUS. Consejo General de Colegios Oficiales de Farmaceuticos [Internet]. 2021 [cited 2021 June 2]. Available from: https://botplusweb.portalfarma.com/botplus.aspx.
   Google Scholar
• Gorodetskaya I, Zenios S, Mcculloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68(6):2801–2808.
   PubMed Web of Science ®Google Scholar
• Lee AJ, Morgan C, Conway P, et al. Characterisation and comparison of health-related quality of life for patients with renal failure. Curr Med Res Op. 2005;21(11):1777–1783.
   PubMed Web of Science ®Google Scholar
• Göhler A, Geisler BP, Manne JM, et al. Utility estimates for decision–analytic modeling in chronic heart Failure-Health states based on New York heart association classes and number of rehospitalizations. Value in Health. 2009;12(1):185–187.
   PubMed Web of Science ®Google Scholar
• Kent S, Briggs A, Eckermann S, et al. Are value of information methods ready for prime time? An application to alternative treatment strategies for NSTEMI patients. Int J Technol Assess Health Care. 2013;29(4):435–442.
   PubMed Web of Science ®Google Scholar
• Sennfält K, Magnusson M, Carlsson P. Comparison of hemodialysis and peritoneal dialysis–a cost-utility analysis. Perit Dial Int. 2002;22(1):39–47.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Clinical guideline [CG125]: chronic kidney disease (stage 5): peritoneal dialysis. National Institute for Health and Care Excellence. [Internet]. 2021 [cited 2021 July 21]. Available from: https://www.nice.org.uk/guidance/cg125.
   Google Scholar
• Ministerio de Sanidad. Listado de medicamentos afectados por las deducciones del Real Decreto-Ley 8/2010 [List of drugs affected by the deductions of the Royal Decree-Law 8/2010]. Ministerio de Sanidad. 2021 [cited 2021 July 1]. Available from: https://www.mscbs.gob.es/profesionales/farmacia/pdf/DeduccionesJulio2021.pdf.
   Google Scholar
• National Institute for Health and Care Excellence. Clinical guideline [NG107]: renal replacement therapy and conservative management. National Institute for Health and Care Excellence [Internet]. 2021 [cited 2021 July 21]. Available from: https://www.nice.org.uk/guidance/ng107.
   Google Scholar
• Szende A, Janssen B, Cabases J, editors. Self-reported population health: an international perspective based on EQ-5D. Dordrecht (The Netherlands): Springer; 2014.
   Google Scholar
• Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314(2):151.
   PubMed Web of Science ®Google Scholar
• Jiménez-Marrero S, Cainzos-Achirica M, Monterde D, et al. Impact on clinical outcomes and health costs of deranged potassium levels in patients with chronic cardiovascular, metabolic, and renal conditions. Rev Esp Cardiol. 2021;74(4):312–320.
   PubMed Web of Science ®Google Scholar
• Collins AJ, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol. 2017;46(3):213–221.
   PubMed Web of Science ®Google Scholar
• Widén J, Ivarsson M, Schalin L, et al. Cost-Effectiveness analysis of patiromer in combination with renin-angiotensin-aldosterone system inhibitors for chronic kidney disease in Sweden. PharmacoEconomics. 2020;38(7):747–764.
   PubMed Web of Science ®Google Scholar
• Bounthavong M, Adamson R, Dolan C, et al. The cost-effectiveness analysis of patiromer and renin-angiotensin-aldosterone system inhibitors therapy in diabetic nephropathy patients with hyperkalemia. J Manag Care Spec Pharm. 2018;24:S86.
   Google Scholar
• Bounthavong M, Butler J, Dolan CM, et al. Cost-effectiveness analysis of patiromer and spironolactone therapy in heart failure patients with hyperkalemia. PharmacoEconomics. 2018;36(12):1463–1473.
   PubMed Web of Science ®Google Scholar
• De Sequera P, Bover R, Ivanova Y, et al. Análisis económico del uso de patiromer en España [Economic analysis of the use of patiromer in Spain]. Málaga (Spain): 22 Congreso Nacional de Hospitales y Gestión Sanitaria; 2021. Spanish.
   Google Scholar
• Brück K, Jager KJ, Zoccali C, et al. Different rates of progression and mortality in patients with chronic kidney disease at outpatient nephrology clinics across Europe. Kidney Int. 2018;93(6):1432–1441.
   PubMed Web of Science ®Google Scholar